000119319 001__ 119319
000119319 005__ 20240228145432.0
000119319 0247_ $$2doi$$a10.1177/0271678X16630322
000119319 0247_ $$2pmid$$apmid:26861817
000119319 0247_ $$2ISSN$$a0271-678X
000119319 0247_ $$2ISSN$$a1559-7016
000119319 0247_ $$2altmetric$$aaltmetric:5307532
000119319 037__ $$aDKFZ-2017-00074
000119319 041__ $$aeng
000119319 082__ $$a610
000119319 1001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b0$$eFirst author$$udkfz
000119319 245__ $$aAssessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma.
000119319 260__ $$aThousands Oaks, Calilf.$$bSage$$c2017
000119319 3367_ $$2DRIVER$$aarticle
000119319 3367_ $$2DataCite$$aOutput Types/Journal article
000119319 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525764853_9511
000119319 3367_ $$2BibTeX$$aARTICLE
000119319 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119319 3367_ $$00$$2EndNote$$aJournal Article
000119319 520__ $$aAntiantiogenic therapy with bevacizumab in recurrent glioblastoma is currently understood to both reduce microvascular density and to prune abnormal tumor microvessels. Microvascular pruning and the resulting vascular normalization are hypothesized to reduce tumor hypoxia and increase supply of systemic therapy to the tumor; however, the underlying pathophysiological changes and their timing after treatment initiation remain controversial. Here, we use a novel dynamic susceptibility contrast MRI-based method, which allows simultaneous assessment of tumor net oxygenation changes reflected by the tumor metabolic rate of oxygen and vascular normalization represented by the capillary transit time heterogeneity. We find that capillary transit time heterogeneity, and hence the oxygen extraction fraction combine with the tumoral blood flow (cerebral blood flow) in such a way that the overall tumor oxygenation appears to be worsened despite vascular normalization. Accordingly, hazards for both progression and death are found elevated in patients with a greater reduction of tumor metabolic rate of oxygen in response to bevacizumab and patients with higher intratumoral tumor metabolic rate of oxygen at baseline. This implies that tumors with a higher degree of angiogenesis prior to bevacizumab-treatment retain a higher level of angiogenesis during therapy despite a greater antiangiogenic effect of bevacizumab, hinting at evasive mechanisms limiting bevacizumab efficacy in that a reversal of their biological behavior and relative prognosis does not occur.
000119319 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000119319 588__ $$aDataset connected to CrossRef, PubMed,
000119319 7001_ $$aMouridsen, Kim$$b1
000119319 7001_ $$0P:(DE-He78)77588f5b9413339755a66e739d316c7d$$aRadbruch, Alexander$$b2$$udkfz
000119319 7001_ $$0P:(DE-He78)ea7f20e71e3cb1a864c23f2f09f0b0b9$$aKurz, Felix Tobias$$b3$$udkfz
000119319 7001_ $$aEidel, Oliver$$b4
000119319 7001_ $$aWick, Antje$$b5
000119319 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b6$$udkfz
000119319 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b7$$udkfz
000119319 7001_ $$aBendszus, Martin$$b8
000119319 7001_ $$aØstergaard, Leif$$b9
000119319 7001_ $$0P:(DE-He78)3da06896bf2a50a84d40c33c3b7a9b3e$$aKickingereder, Philipp$$b10$$eLast author$$udkfz
000119319 773__ $$0PERI:(DE-600)2039456-1$$a10.1177/0271678X16630322$$gVol. 37, no. 2, p. 485 - 494$$n2$$p485 - 494$$tJournal of cerebral blood flow & metabolism$$v37$$x1559-7016$$y2017
000119319 909CO $$ooai:inrepo02.dkfz.de:119319$$pVDB
000119319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)77588f5b9413339755a66e739d316c7d$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000119319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea7f20e71e3cb1a864c23f2f09f0b0b9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000119319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000119319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000119319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3da06896bf2a50a84d40c33c3b7a9b3e$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000119319 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000119319 9141_ $$y2017
000119319 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CEREBR BLOOD F MET : 2015
000119319 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119319 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119319 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119319 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000119319 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000119319 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119319 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119319 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119319 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119319 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000119319 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000119319 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000119319 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x0
000119319 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x1
000119319 9201_ $$0I:(DE-He78)E012-20160331$$kE012$$lNeuroonkologische Bildgebung$$x2
000119319 980__ $$ajournal
000119319 980__ $$aVDB
000119319 980__ $$aI:(DE-He78)E010-20160331
000119319 980__ $$aI:(DE-He78)G370-20160331
000119319 980__ $$aI:(DE-He78)E012-20160331
000119319 980__ $$aUNRESTRICTED